In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as ...

Cancer biotech Viracta Therapeutics has closed its doors, laying off all employees and winding down operations. The San Diego ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor.

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

Omega Therapeutics has almost reached the end. With cash running low, the Novo Nordisk-partnered biotech has struck a deal ...

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of chief ...

The U.S. tariffs on China include a broad 10% levy on imported goods. China’s response was more targeted, with 15% tariffs on ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

Jan. 31, the CDC's chief science officer sent an internal email that informed the agency’s division heads that all papers ...